Printer Friendly

Coronado commences TSO trial in pediatric patients with autism spectrum disorder.

M2 EQUITYBITES-April 14, 2014-Coronado commences TSO trial in pediatric patients with autism spectrum disorder


Coronado Biosciences (CNDO), a US-based bioscences company, has started an investigator-initiated trial evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of paediatric patients with autism spectrum disorder (ASD), it was reported on Friday.

Dr. Itai Berger, director of the Neuro-Cognitive Center at the Hadassah-Hebrew University Medical Center in Jerusalem, Israel, is carrying out the trial.

The trial is intended to test the safety of TSO compared to a placebo in approximately 60 paediatric patients between the ages of 6 and 17 years who meet criteria for the diagnosis of ASD and efficacy signals on irritability, repetitive behaviours, global functioning and social cognition.

In the 16-week randomised, double-blind, placebo-controlled trial, patients will receive a placebo, 2500 TSO or 7500 TSO every other week.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 14, 2014
Previous Article:Quad/Graphics prices private offering of USD300m senior notes due 2022.
Next Article:Intapp takes over risk management software firm TFG.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters